Inactive

Department of Veterans Affairs Veterans Health Administration (VHA) Sources Sought Notice Obtain medication. This is a Sources Sought notice and not a request for quotes. This request is solely for th... Department of Veterans Affairs Veterans Health Administration (VHA) Sources Sought Notice Obtain medication. This is a Sources Sought notice and not a request for quotes. This request is solely for the purpose of conducting market research to enhance VHA s understanding of your company s offered services and capabilities. The Government will not pay any costs for responses submitted in response to this Source Sought Notice. This Sources Sought notice provides an opportunity for respondents to submit their capability and availability to provide the service requirement described below. Vendors are being invited to submit information relative to their potential to fulfill this requirement, in the form of a capability response that addresses the specific requirement identified in this Sources medication and Temple, TX. Refer to the General Requirements section below for the requested product description. This Sources Sought is Sought. The Veterans Health Administration (VHA) is seeking to obtain brand name or equal to facilitate the Contracting Officer s review of the market base, for acquisition planning, size determination, and procurement strategy. General Requirements: Brand name or equal medication are needed for the Temple, TX in accordance with the following requirements: ITEM NUMBER DESCRIPTION OF SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0001 210.00 UN $00.00 $00.00 C1 INHIBITOR (HUMAN) 2000UNITS/VIL INJ,SOLN HAEGARDA 2000UNITS/VIL INJ,SOLN GRAND TOTAL $00.00 STATEMENT OF WORK C1 Inhibitor (Human) 2000 Units/VIL Inj, SOLN I. INTRODUCTION: The mission of the Central Texas Veterans Health Care System (CTVHCS) is to provide the highest quality health care to our nation's Veterans. In order to accomplish this mission, we must protect the health and safety of patients, employees, and visitors. II. GENERAL REQUIREMENTS: Monthly order of 20 injections of C1 Inhibitor (Human) 2000 units/Vil Vendor must be licensed and authorized to sell/dispense medication Base Year POP: 01 Jan 2022- 31 Dec 2022 Option Year 1: 01 Jan 2023- 31 Dec 2023 Option Year 2: 01 Jan 2024- 31 Dec 2024 Option Year 3: 01 Jan 2025- 31 Dec 2025 Option Year 4: 01 Jan 2026- 31 Dec 2026 III. SALIENT CHARACTERISTICS: Drug must be brand name or equal to HAEGARDA The treatment must be subcutaneous and have would prevent hereditary angioedema (HAE) attacks. Must be a C1 Esterase Inhibitor Subcutaneous [Human] Must be plasma-derived and able to be self-administered Must be approved by the United States for use in prophylaxis to prevent hereditary angioedema III. Point of contact: Brandi Lujan Brandi.Lujan@va.gov (254) 743-0250 The Department of Veterans Affairs is seeking both manufacturers and/or distributors of the exact match or functionally equivalent equipment/ services to the following listed above. 52.211-6 Brand Name or Equal. As prescribed in 11.107(a), insert the following provision: Brand Name or Equal (Aug 1999)      (a) If an item in this solicitation is identified as brand name or equal, the purchase description reflects the characteristics and level of quality that will satisfy the Government s needs. The salient physical, functional, or performance characteristics that equal products must meet are specified in the solicitation.      (b) To be considered for award, offers of equal products, including equal products of the brand name manufacturer, must-           (1) Meet the salient physical, functional, or performance characteristic specified in this solicitation;           (2) Clearly identify the item by-                (i) Brand name, if any; and                (ii) Make or model number;           (3) Include descriptive literature such as illustrations, drawings, or a clear reference to previously furnished descriptive data or information available to the Contracting Officer; and           (4) Clearly describe any modifications the offeror plans to make in a product to make it conform to the solicitation requirements. Mark any descriptive material to clearly show the modifications.      (c) The Contracting Officer will evaluate equal products on the basis of information furnished by the offeror or identified in the offer and reasonably available to the Contracting Officer. The Contracting Officer is not responsible for locating or obtaining any information not identified in the offer.      (d) Unless the offeror clearly indicates in its offer that the product being offered is an equal product, the offeror shall provide the brand name product referenced in the solicitation. (End of clause) VAAR 852.212-72 Gray Market Items: a) Gray market items are Original Equipment Manufacturers' (OEM) goods sold through unauthorized channels in direct competition with authorized distributors. This procurement is for new OEM medical equipment only for VA Medical Centers. No remanufactures or gray market items will be acceptable. (b) Vendor shall be an OEM, authorized dealer, authorized distributor or authorized reseller for the proposed equipment/system, verified by an authorization letter or other documents from the OEM, such that the OEM's warranty and service are provided and maintained by the OEM. All software licensing, warranty and service associated with the equipment/system shall be in accordance with the OEM terms and conditions. (End of clause) FAR 52.212-2 Evaluation-Commercial Items: A copy of the authorized distributor letter from the contractor to verify that you are an authorized distributor of the products/services SHALL BE SUBMITTED WITH THE QUOTE AND IS MANDATORY. Please title email with RFI 36C25721Q1294 C1 Inhibitor